Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cipaglucosidase alfa/miglustat in children with infantile-onset Pompe disease
NL-OMON58905Phase 3Recruiting
- Sponsor
- Amicus Therapeutics
- Start
- Nov 2025
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cipaglucosidase alfa, miglustat in Pompe disease, sponsored by Amicus Therapeutics. Started Nov 2025; status: recruiting.
02
Drugs
cipaglucosidase alfamiglustat
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NL-OMON58905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58905.